The effect of iNeo-Vac-P01, a personalized neoantigen-based peptide vaccine, was examined in the treatment of PC, and the iNeo-Vac-P01 could enhance the clinical efficacy of PC (41). This evidence concerns the gene H3P21 and pachyonychia congenita.